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OBJECTIVES: Pharmaceutical companies have designed prescription drug 
coupons and copay cards (CCCs) programs to maintain brand name medication 
loyalty, especially for medications that have just, or are about to lose their 
patent. The objective of this study is to evaluate perceptions of retail 
pharmacists about coupon and copay card (CCC) programs. METHODS: 
Pharmacists in the state of Arkansas, USA, were surveyed online. Questions on 
5-point likert scale focused on pharmacist’s perceptions towards CCC's regarding 
benefits to patients, public health, medication compliance, pharmacist workload, 
as well as barriers to pharmacy practice. Chi-square and multivariate logistic 
models were used to analyze the data. RESULTS: Of the approximately 1200 
subjects 325 took the survey. Excluding missing values, 214 subjects were 
included in final analysis. Of these, 56% were male, 47% were less than 35 years 
of age, and 46% worked in a franchise or chain pharmacy, 40% were located in 
urban or suburban areas, 60% were in semi-urban or rural areas. Regression 
results indicated that full-time pharmacist practicing in larger pharmacies and 
processing higher numbers of CCCs had more favorable views towards patient 
satisfaction with CCCs (all p-values<0.05). Most pharmacists were reluctant to 
express that CCCs saved patients money, were good for public health, or 
improved medication compliance. Most pharmacists agreed that CCCs increased 
pharmacy workload, however highly satisfied pharmacist with proper staffing 
disagreed. Female pharmacists were more likely to explain CCC use to patients. 
Pharmacists working in high-volume chain and urban environments were least 
likely to state difficulties processing CCC transactions. All p-values in regression 
results reported above were <0.05 with odds ratios ranging from 1.05 to 2.5 (note: 
individual p-values and odds ratios are too many to report because of word 
limit). CONCLUSIONS: With increasing prevalence of CCCs, this study provides 
key insights into perceptions of pharmacists.  
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OBJECTIVES: Enrollment in Medicare Part D is voluntary; however, mechanisms 
exist to encourage early enrollment and improve risk pooling, including a 
permanent premium penalty associated with delayed enrollment and restricted 
enrollment periods. This study examined whether a health shock would create 
adequate incentives to overcome the penalties associated with late enrollment. 
METHODS: Using enrollment and claims from a random 5% sample of Medicare 
beneficiaries from 2006 to 2008, we observed Part D enrollment decisions among 
beneficiaries who had failed to enroll in Part D at first eligibility (N=207,674). A 
health shock was defined as a hospital admission due to a drug-intensive 
chronic condition. Multivariable logistic regression examined the impact of a 
health shock on the probability of late Part D enrollment, controlling for 
beneficiary demographics, pre-existing chronic conditions, preventive service 
use, and admission to a facility. We also examined whether timing of the 
hospitalization relative to the next available enrollment period influenced the 
likelihood of Part D enrollment. RESULTS: Eighteen percent of beneficiaries in 
the cohort enrolled late into Part D. Initial and subsequent hospitalizations for 
drug-intensive conditions were associated with 5 and 7 percentage point 
increases in the probability of Part D enrollment, respectively (p<0.01). A gap 
from the time of hospitalization to the next coverage period was associated with 
a lower likelihood of enrollment among non-Low Income Subsidy (LIS) 
recipients, but had no relationship for LIS enrollment, which is not restricted to 
enrollment periods. CONCLUSIONS: Health shocks were associated with an 
increased likelihood of late Part D enrollment, but many beneficiaries remained 
without Part D coverage despite deterioration in their health status and expected 
increased need for drugs. Non-enrollees were forced to either absorb the full cost 
of medications or forgo them, which can have negative effects on health and, the 
potential to increase Parts A and B spending.  
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OBJECTIVES: Order in which warning information is presented on the over-the-
counter medication Drug Facts panel could enhance patient safety. This study 
assessed the effect of placement of warning information on OTC Drug Facts 
panel to provide guidance to the FDA in enhancing appropriate product use. 
METHODS: Two experimental labels (current and new) were developed from an 
existing marketed drug product by varying the sequence of information to- uses, 
directions, other information and warnings (new) vs uses, warnings, directions 
and other information (current). In this repeated measure experimental study, 
each participant evaluated labels on ease of use and purchase intention using an 
eleven point scale with appropriate scale anchors. The order in which 
participants viewed the label was randomized. Mean score for ease of use and 
purchase intention was contrasted between labels using match paired t-test. 
RESULTS: Of the 297 study participants (71% response rate), majority were males 
(60.4%) with a mean (±SD) age of 21.3 (±1.8) years. More than half (55%) indicating 
they often read labels, while 70% were currently not on any medications. The 
mean (±SD) scores were significantly (p<0.0001) higher for ease of use for the 
new (8.0±1.2) as compared to the current label design (6.8±1.2). Similarly the 
mean purchase intention were also significantly (p<0.0003) higher for the new 
label design (7.8±1.4) compared to current label (7.4±1.2). CONCLUSIONS: The 
prototype new label developed with congruent information where uses and 
directions were clustered and were followed by warnings was perceived better. 
This information can help guide the FDA to conduct more studies and develop 
policy changes as necessary to improve information comprehension from OTC 
Drug Facts panel.  
 
PHP108  
PERCEPTIONS AND BARRIERS TO PARTICIPATION IN CLINICAL RESEARCH OF 
PRIMARY CARE PHYSICIANS  
Atzinger CB, Siebenaler J 
OptumInsight, Eden Prairie, MN, USA  
BACKGROUND: The number of physicians willing to participate in clinical 
research has been on the decline in the US and Europe for the last decade. This 
trend is contrary to projected research needs as a result of expanded regulatory 
requirements for post-marketing studies of new drugs and devices and the need 
for more comparative effectiveness data. The problem is further magnified when 
considering the need for research data from the front lines of primary medical 
care, where the majority of patients receive their initial and ongoing care. 
OBJECTIVES: The primary objective of this study is to assess primary care 
physician (PCP) perceptions toward practice-based clinical research and identify 
barriers they face when deciding to participate in projects. METHODS: A web-
based survey was distributed to over 4000 PCPs over a 30-day period. 
Respondents were asked about demographics, practice type, practice size, and 
prior clinical research experience. Respondents were divided into two cohorts 
based on prior research experience. Respondents were asked to evaluate the 
value of clinical research and barriers to participation. RESULTS: Survey 
responses were received from 109 PCPs, who were divided into two cohorts 
based on overall research experience. The cohorts were well matched for age, 
gender, specialty, practice size, and patient volume. Approximately 40% of sites 
with minimal research experience responded negatively to the value of clinical 
research, its impact on patient care or benefit to patients. Over 50% reported that 
and that their patients would not be interested in participation in research, 
regardless of study design, nor would they be willing to refer patients to 
physicians conducting research in which they patient could benefit. 
CONCLUSIONS: Sponsors must work more diligently to demonstrate the value of 
practice-based research and create incentives in order to recruit community-
based physicians for clinical research studies.  
 
PHP109  
OPIOID ABSTINENCE IN OPIOID DEPENDENT PATIENTS INFECTED WITH HCV 
IN TREATMENT WITH BUPRENORPHINE  
Dweik D 
Washington State University, Spokane, WA, USA  
OBJECTIVES: HCV infection rates have been gradually increasing for the past 10 
years in the US with drug injection being reported as a primary cause. 
Buprenorphine, with its unique pharmacological profile is a common form of 
treatment for opioid dependence. The aim of this analysis was to determine 
whether opioid-dependent patients infected with HCV and being treated with 
buprenorphine are less likely to achieve the same levels of opioid abstinence as 
those who are not infected. METHODS: The data for this investigation came from 
the National Drug Abuse Treatment Clinical Trial Network study 0003, where, 
after buprenorphine stabilization, the effects of a 7 versus a 28 day tapering 
schedule was compared . Missed urinalyses were coded as positive for opioids. 
Binary logistic regression models were used to test the likelihood of providing an 
opioid-positive urine at baseline (immediately following stabilization), and at the 
end of the treatment period. An ordered logistic regression model tested the 
presence of HCV on the total number of positive urine tests submitted during the 
treatment period. RESULTS: A total of 35.73%of the participants in the overall 
sample tested positive for the HCV antibody. At baseline, there was a 60% 
increase in the odds of HCV patients testing positive/missing for opioid use, 
relative to non-HCV participants. there was a significant effect of HCV status on 
the total number of opioid positive urines submitted during the treatment 
period. However, HCV status was not significantly associated with the likelihood 
of a positive/missing urinalysis at the end of the treatment period. 
CONCLUSIONS: Individuals infected with HCV are less likely to provide opioid-
free urine samples while being treated for opioid dependence with 
buprenorphine. This is an important, albeit exploratory finding that could 
significantly aid in developing future treatment strategies in managing HCV-
infected opioid-dependent patients.  
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OBJECTIVES: Most accounts put the research and development cost of bringing a 
new drug to market close to $1B USD (Adams and Brantner, 2010; Dimasi, et al., 
2003). At this price, manufacturers cannot afford to launch a product that fails to 
meet market expectations, yet often products do not perform as anticipated. 
This effort looks at high-profile FDA approvals and evaluates the market 
performance with particular emphasis on exploring the reasons drugs do not 
meet the predicted revenue targets in the first year of sales. METHODS: We 
examined the 2010 and 2011 drug approvals to select the most appropriate NME 
to examine. Using data from EvaluatePharma®, we compared the forecasted 
annual sales estimate just prior to launch with the actual annual sales in the 
first year on the market. For the products that failed to meet expectations we 
